Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

SWOG-9245 Collecting and Storing Tissue Samples From Patients With Relapsed or Recurrent Non-Hodgkin Lymphoma After Treatment on a Southwest Oncology Group Clinical Trial

This study has been completed.
Sponsor:
Collaborator:
Information provided by (Responsible Party):
Southwest Oncology Group
ClinicalTrials.gov Identifier:
NCT00898872
First received: May 9, 2009
Last updated: May 17, 2013
Last verified: May 2013

May 9, 2009
May 17, 2013
March 1993
July 2011   (final data collection date for primary outcome measure)
Acquisition of snap-frozen lymphoma tissues [ Time Frame: July 2011 ] [ Designated as safety issue: No ]
  • Acquisition of snap-frozen lymphoma tissues [ Designated as safety issue: No ]
  • Development of standard procedures for routine acquisition, banking, and study of lymphoma tissues within the SWOG [ Designated as safety issue: No ]
  • Establishment of clinical correlations via presently activated phenotyping studies and future projected molecular studies assessing specimen DNA and RNA status [ Designated as safety issue: No ]
  • Biology of therapy failure in relationship to changes in pretreatment and post-treatment immunophenotypic data [ Designated as safety issue: No ]
Complete list of historical versions of study NCT00898872 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
SWOG-9245 Collecting and Storing Tissue Samples From Patients With Relapsed or Recurrent Non-Hodgkin Lymphoma After Treatment on a Southwest Oncology Group Clinical Trial
Central Lymphoma Repository Tissue Procurement Protocol for Relapse or Recurrent Disease

RATIONALE: Collecting and storing samples of tissue from patients with non-Hodgkin lymphoma to study in the laboratory may help the study of cancer in the future.

PURPOSE: This laboratory study is collecting and storing tissue samples from patients with relapsed or recurrent non-Hodgkin lymphoma after treatment on a Southwest Oncology Group (SWOG) clinical trial.

OBJECTIVES:

  • Acquire fresh snap-frozen lymphoma tissue from patients with relapsed or recurrent non-Hodgkin lymphoma after treatment on a Southwest Oncology Group (SWOG) clinical trial.
  • Establish a standard set of procedures for routine acquisition, banking, and study of lymphoma tissues within the SWOG.
  • Use repository tissue to establish clinical correlations via presently activated phenotyping studies and future projected molecular studies assessing specimen DNA and RNA status.
  • Examine the biology of therapy failure in relationship to changes in pretreatment and post-treatment immunophenotypic data.

OUTLINE: This is a multicenter study.

Tissues collected at biopsy are snap-frozen and archived for future molecular and genetic studies.

PROJECTED ACCRUAL: Not specified

Observational
Time Perspective: Retrospective
Not Provided
Not Provided
Non-Probability Sample

Patients who consented to SWOG 9245 for banking

Lymphoma
Other: cryopreservation
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
32
July 2011
July 2011   (final data collection date for primary outcome measure)

DISEASE CHARACTERISTICS:

  • Diagnosis of relapsed or recurrent non-Hodgkin lymphoma (NHL)
  • Previously registered on 1 of the following SWOG clinical trials for previously untreated NHL:

    • SWOG-8410
    • SWOG-8503
    • SWOG-8508
    • SWOG-8516
    • SWOG-8736
    • SWOG-8809
    • SWOG-8907
    • SWOG-8954
    • SWOG-9125
    • SWOG-9240
    • SWOG-9320
    • SWOG-9349
    • SWOG-9432
    • SWOG-9501
    • SWOG-9703
    • SWOG-S9704
    • SWOG-9800
  • Tissue samples of relapsed or recurrent disease available

PATIENT CHARACTERISTICS:

  • Not specified

PRIOR CONCURRENT THERAPY:

  • See Disease Characteristics
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00898872
CDR0000455162, SWOG-9245, U10CA032102
No
Southwest Oncology Group
Southwest Oncology Group
National Cancer Institute (NCI)
Study Chair: Thomas Grogan, MD University of Arizona
Study Chair: Thomas P. Miller, MD University of Arizona
Study Chair: Richard I. Fisher, MD James P. Wilmot Cancer Center
Southwest Oncology Group
May 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP